Macro Tsimmis

intelligently hedged investment

Élan (ELN) update #3

Posted by intelledgement on Tue, 31 Jul 07

An FDA advisory committee voted 12-3 today to recommend approval of the use of Tysabri for Crohn’s disease patients in the USA. The FDA is not required to follow the advice of their advisory committees, but generally does. A decision by the agency is expected by 15 October.

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: